










Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial

Stefano Partelli^{1,2} , Sara Massironi^{3,4} , Alessandro Zerbi^{5,6}, Patricia Niccoli⁷, Wooil Kwon⁸ , Luca Landoni⁹, Francesco Panzuto¹⁰, Ales Tomazic¹¹, Alberto Bongiovanni¹², Gregory Kaltsas¹³, Alain Sauvanet¹⁴, Emilio Bertani¹⁵, Vincenzo Mazzaferro¹⁶ , Martyn Caplin¹⁷, Thomas Armstrong¹⁸, Martin O. Weickert¹⁹, John Ramage²⁰, Eva Segelov²¹ , Giovanni Butturini²², Stefan Staettner²³, Mauro Cives²⁴, Andrea Frilling²⁵, Carol Anne Moulton^{26,27}, Jin He²⁸ , Florian Boesch²⁹, Andreas Selberheer³⁰, Orit Twito^{31,32}, Antonio Castaldi³³ , Claudio G. De Angelis³⁴, Sebastien Gaujoux³⁵ , Katharina Holzer³⁶, Colin H. Wilson³⁷, Hussein Almeamar³⁸, Emanuel Vigia³⁹, Francesca Muffatti^{1,2}, Martina Lucà^{3,4}, Andrea Lania^{5,6}, Jacques Ewald⁷, Hongbeom Kim⁸ , Roberto Salvia⁹, Maria Rinzivillo¹⁰, Alojz Smid⁴⁰, Andrea Gardini⁴¹, Marina Tsoli¹³, Olivia Hentic¹⁴, Samuele Colombo¹⁵, Davide Citterio¹⁶, Christos Toumpanakis¹⁷, Emma Ramsey¹⁸, Harpal S. Randeve⁴², Ray Srirajaskanthan²⁰, Daniel Croagh²¹, Paolo Regi²², Silvia Gasteiger⁴³, Pietro Invernizzi^{3,4}, Cristina Ridolfi⁴⁴, Marc Giovannini⁷, Jin-Young Jang⁸, Claudio Bassi⁹ and Massimo Falconi^{1,2,*}

¹School of Medicine, Vita-Salute San Raffaele University, Milan, Italy

²Pancreas Translational and Clinical Research Centre, Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

³Division of Gastroenterology and Centre for Autoimmune Liver Diseases, San Gerardo Hospital, Monza, Italy

⁴Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

⁵Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

⁶IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

⁷Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France

⁸Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

⁹General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona Hospital Trust, Verona, Italy

¹⁰Digestive Disease Unit, ENETS Centre of Excellence, Sant' Andrea University Hospital, Rome, Italy

¹¹Department of Abdominal Surgery, University Medical Centre, Ljubljana, Slovenia

¹²Osteonology and Rare Tumours Centre (CDO-TR), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy

¹³First Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

¹⁴Department of Pancreatology, Hôpital Beaujon, University of Paris, Paris, France

¹⁵Division of Gastrointestinal Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy

¹⁶Gastrointestinal and Hepato-Pancreatic Surgery and Liver Transplantation Unit, Fondazione, IRCCS Istituto Nazionale Tumori (INT, National Cancer Institute) and Università degli Studi di Milano, Milan, Italy

¹⁷ENETS Centre of Excellence, Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK

¹⁸Department of Hepatobiliary Surgery, Wessex NET Group ENETS Centre of Excellence, University Hospital Southampton, Southampton, UK

¹⁹ARDEN NET Centre, ENETS Centre of Excellence, University Hospitals Coventry and Warwickshire NHS Trust and Warwick Medical School, University of Warwick, Coventry, UK

²⁰Kings Health Partners NET Centre, Kings College Hospital London, London, UK

²¹Department of Oncology and Surgery (School of Clinical Sciences at Monash Health), Monash University, Clayton, Victoria, Australia

²²Department of Surgery, Pederzoli Hospital, Peschiera del Garda, Italy

²³Department of General, Visceral and Vascular Surgery, Salzkammergutklinikum Vöcklabruck, Vöcklabruck, Austria

²⁴Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy

²⁵Department of Surgery and Cancer, Imperial College London, London, UK

²⁶Division of General Surgery, University of Toronto, Toronto, Ontario, Canada

²⁷Department of Surgery, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada

²⁸Department of Surgery, Johns Hopkins University School of Medical, Baltimore, Maryland, USA

²⁹Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany

³⁰Section Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University, Vienna, Austria

³¹Endocrine Institute, Meir Medical Center, Kfar-Sava, Israel

³²Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

³³Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

³⁴Gastroenterology Unit, Department of Medical Sciences, City of Health and Science Hospital, Turin, Italy

³⁵Department of Digestive, Hepatobiliary and Endocrine Surgery, Paris Sorbonne University, Pitié Salpêtrière Hospital, Paris, France

³⁶Department of Visceral-, Thoracic- and Vascular Surgery, Section of Endocrine Surgery, University Hospital Marburg (UKGM), Marburg, Germany

³⁷Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK

³⁸National NET Centre and ENETS Centre of Excellence, St Vincent's University Hospital, Dublin, Ireland

³⁹Hepato-Biliary-Pancreatic and Transplantation Centre, Curry Cabral Hospital, CHULC, Lisbon, Portugal

⁴⁰Department of Gastroenterology and Hepatology, University Medical Centre Ljubljana, Ljubljana, Slovenia

⁴¹General and Oncological Surgery Unit, Morgagni-Pierantoni Hospital, Forlì, Italy

⁴²Warwick Medical School, University of Warwick, Coventry, UK

⁴³Department of Visceral, Transplantation and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria

⁴⁴Pancreatic Surgery Unit, Humanitas Clinical and Research Hospital—IRCCS, Rozzano, Milan, Italy

*Correspondence to: Massimo Falconi, Pancreas Translational and Clinical Research Centre, Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute University, Via Olgettina, 60 20132, Milan, Italy (e-mail: falconi.massimo@hsr.it)

Received: March 21, 2022. Revised: May 18, 2022. Accepted: July 14, 2022

© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

The incidence of non-functioning pancreatic neuroendocrine neoplasms (NF-PanNENs) has increased recently¹. Traditionally, surgery has been the treatment of choice for localized NF-PanNENs, although evidence has emerged that active surveillance could be advocated for most asymptomatic tumours no larger than 2 cm²⁻⁷. However, the practice of active surveillance varies considerably and, contrary to current recommendations⁸⁻¹⁰, many patients still undergo surgical resection¹¹⁻¹³.

Current evidence is limited by the retrospective design of studies and the small number of patients. The present study is the most extensive prospective investigation to date on small, asymptomatic NF-PanNENs. The aim was to define the optimal management of incidentally found, sporadic NF-PanNENs no larger than 2 cm.

Methods

This was a prospective, non-randomized, international, multicentre, cohort study (NCT03084770). This report describes the results of the prespecified interim analysis. Overall, 41 centres have been included. The study protocol was published previously¹⁴ (*Appendix S1*). Briefly, CT or MRI was mandatory for all patients. The diagnosis must have been proven by a positive fine-needle aspiration (biopsy) (FNA(B)) or positive ⁶⁸Ga-labelled DOTA PET. The treatment—active surveillance or surgical resection—was decided by the referring centre. Because current guidelines⁸⁻¹⁰ suggest surveillance for asymptomatic NF-PanNENs 2 cm or smaller in size, treating physicians were asked to indicate the reason for choosing surgery. An aggressive feature was defined by one or more of the following features: Ki-67 over 20 per cent, perineural invasion, microvascular invasion, nodal metastases, or distant metastases.

Results

The study flow diagram is shown in *Fig. 1*. After initial screening, all the patients had at least positive ⁶⁸Ga-labelled DOTA PET and/or a positive FNA(B) for NF-PanNEN.

Table 1 summarizes demographics and clinical characteristics by the type of management. Younger age, larger tumour size, lower BMI, dilated main pancreatic duct (MPD), and enrolment of the patient in a surgical centre were associated more frequently with surgery. Global quality of life at diagnosis was similar in the two groups (*Fig. S1*). Overall, distant metastases were present in 4 patients (0.08 per cent), all of whom underwent surgery. On multivariable analysis, factors associated with surgery were: age 64 years or less (OR 2.5; $P < 0.001$), radiological size larger than 10 mm (OR 1.9; $P = 0.030$), MPD: over 3 mm (OR 3.4; $P < 0.001$), surgical centre (OR 2.0; $P = 0.012$), and Hospital Anxiety and Depression Scale—anxiety score above 3 and no more than 6 (OR 2.0; $P = 0.029$) (*Table S1*). Indication for surgery was attributed to patient's preference in 42 instances (45 per cent), centre's preference in 37 (39 per cent), MPD dilatation in 11 (12 per cent), and distant metastases in 4 (4 per cent).

Surgical outcomes are summarized in *Table S2*. Minimally invasive, either laparoscopic or robot-assisted, was the preferred approach in 55 per cent of patients. Severe complications (defined as those with a Clavien–Dindo grade¹⁵ of more than III) occurred in 13 per cent of patients whereas the mortality rate

was zero. Final pathological examination characteristics are listed in *Table S3*. The choice of standard pancreatectomy over an atypical resection was justified by the need to perform an adequate lymphadenectomy in 52 patients (54 per cent) and the proximity of the nodule to the MPD in 23 (25 per cent). One or more aggressive histological features were observed in 19 patients (20 per cent). Of these 19 patients, 17 had a radiological tumour size larger than 10 mm. The remaining 2 patients with radiological tumour size less than 10 mm had a dilated MPD on preoperative imaging. In 5 of the 19 patients with aggressive features, the radiological MPD was larger than 3 mm.

After a median follow-up of 25 (i.q.r. 16–35) months, all patients were alive apart from 3 who died from causes unrelated to NF-PanNENs. Only 1 patient in the surgical group, who had liver metastases at diagnosis, eventually developed liver recurrence.

In the surveillance group, 9 patients (2 per cent) underwent surgery during follow-up. The reason for surgery was increasing tumour size in 4 patients, increased MPD dilatation in 3, and patient's preference in 2.

Discussion

A non-operative strategy seems safe as only a negligible fraction of patients had an increase in tumour size and no patient developed distant metastases during follow-up. These results are consistent with the preliminary findings of a recent prospective study⁶, although the present series included a five-fold larger number of patients and compared the two types of management of asymptomatic small NF-PanNENs, leaving the therapeutic decision (surveillance versus surgery) to the treating centres.

Other factors that contributed to the decision to resect a NF-PanNEN of 2 cm or smaller were younger age, tumour size over 1 cm, and the presence of MPD dilatation. Furthermore, patient's preference was the main reason for choosing surgery in many instances. This attitude might be explained by patients' anxiety and by the ongoing debate in the scientific community about the optimal management of these lesions. Moreover, the current guidelines⁸⁻¹⁰ suggest that surveillance is recommended, especially for older patients, and this may explain why young age was an important factor in deciding on a surgical approach more frequently. In the present experience, it was found that nearly 20 per cent of resected tumours had one or more aggressive features. Notably, nearly all the lesions that presented at least one aggressive feature were also larger than 1 cm.

The optimal cut-off for considering NF-PanNENs as low-risk lesions is a matter of ongoing controversy. The European Neuroendocrine Tumor Society⁸ and National Comprehensive Cancer Network¹⁰ guidelines consider observation for lesions no larger than 2 cm. On the other hand, North American Neuroendocrine Tumor Society⁹ guidelines suggest that the treatment of asymptomatic NF-PanNENs between 1 and 2 cm in size should be individualized. The present findings seem to support these latter recommendations. The presence of MPD dilatation should be promptly recognized and always considered as a major sign of concern because of the strong correlation with aggressive features, as described previously¹⁶. Another possible role in predicting the biological behaviour of these small nodules may be played by novel promising biomarkers such as NETest¹⁷. Finally, another important result was the detection of synchronous liver metastases in four patients,

Table 1 Characteristics of patients in ASPEN study

	Overall (n = 500)	Active surveillance (n = 406)	Surgical resection (n = 94)	P§
Sex				0.529
F	238 (47.6)	196 (48.3)	42 (45)	
M	262 (52.4)	210 (51.7)	52 (55)	
Age (years), median (i.q.r.)	64 (54–71)	65 (56–71)	59 (51–68)	<0.001¶
BMI (kg/m²)				0.052
≤ 25	175 (35.0)	134 (33.0)	41 (44)	
> 25	325 (65.0)	272 (67.0)	53 (56)	
Diabetes				0.268
No	417 (83.4)	335 (82.5)	82 (87)	
Yes	83 (16.6)	71 (17.5)	12 (13)	
ECOG PS score				0.305
0	436 (87.2)	349 (86.0)	87 (93)	
1	52 (10.4)	45 (11.1)	7 (7)	
≥ 2	12 (2.4)	12 (2.9)	0 (0)	
Year of diagnosis				0.059
2017–2018	271 (54.2)	212 (52.2)	59 (63)	
2019–2020	229 (45.8)	194 (47.8)	35 (37)	
Site of lesion				0.323
Head	121 (24.2)	101 (24.9)	20 (21)	
Uncinate process	55 (11.0)	48 (11.8)	7 (8)	
Body	167 (33.4)	136 (33.5)	31 (33)	
Tail	157 (31.4)	121 (29.8)	36 (38)	
Radiological tumour size (mm), mean(s.d.)*	13.2 (4.1)	12.9 (3.9)	14.8 (4.5)	<0.010#
rN status				1.000
rN0	499 (99.8)	406 (100)	93 (99)	
rN1	1 (0.02)	0 (0)	1 (1)	
rM status				0.671
rM0	496 (99.2)	406 (100)	90 (96)	
rM1	4 (0.08)	0 (0)	4 (4)	
MPD diameter (mm), mean(s.d.)	2.9 (3.4)	2.5 (3.1)	4.3 (4.0)	0.001#
CgA (ng/ml), median (i.q.r.)	61 (30–36)	60 (25–106)	63 (44–123)	0.259¶
[¹⁸F]FDG PET				0.454
Not performed	427 (85.4)	344 (84.7)	83 (88)	
Negative	55 (11.0)	48 (11.8)	7 (8)	
Positive	18 (3.6)	14 (3.4)	4 (4)	
FNA(B)				0.001
Not performed	170 (34.0)	124 (30.5)	46 (49)	
Negative	45 (9.0)	34 (8.4)	11 (12)	
Positive	285 (57.0)	248 (61.1)	37 (39)	
Tumour grade†				<0.001
PanNET-G1	195 (68.4)	179 (72.2)	16 (43)	
PanNET-G2	22 (7.7)	12 (4.8)	10 (27)	
Not evaluable	68 (23.9)	57 (23.0)	11 (30)	
Surgical centre				0.006
No	178 (35.6)	156 (38.4)	22 (23)	
Yes	322 (64.4)	250 (61.6)	72 (77)	
HADS score‡				0.295
≤ 5	167 (33.4)	142 (35.0)	25 (27)	
6–12	172 (34.4)	137 (33.7)	35 (37)	
> 12	161 (32.2)	127 (31.3)	34 (36)	
HADS—anxiety score‡				0.108
≤ 3	148 (29.6)	126 (31.0)	22 (23)	
4–6	178 (35.6)	136 (33.5)	42 (45)	
> 6	174 (34.8)	144 (35.5)	30 (32)	
HADS—depression score‡				0.563
≤ 2	114 (22.8)	95 (23.4)	19 (20)	
3–4	207 (41.4)	170 (41.9)	37 (39)	
> 4	179 (35.8)	141 (34.7)	38 (41)	

Values are n (%) unless otherwise indicated. *Maximum size on radiological imaging or endoscopic ultrasonography. †Evaluated for patients with positive fine-needle aspiration (biopsy) (FNA(B) specimen. ‡Categorized by tertiles of Hospital Anxiety and Depression Scale (HADS) distribution. ECOG PS, Eastern Cooperative Oncology Group performance status; MPD, main pancreatic duct; CgA, chromogranin A; FDG, fluorodeoxyglucose. §Pearson χ^2 test, except ¶Wilcoxon Mann–Whitney test and #t test.

which demonstrates a real, although rare, potential for distant spread also among NF-PanNENs of 2 cm or smaller.

In conclusion, active surveillance is the preferred approach for sporadic, asymptomatic, NF-PanNENs no larger than 2 cm. An active surveillance strategy seems safe, but the measurable risk of distant metastases, as well as the presence of histological

characteristics of aggressiveness in almost one-fifth of operated tumours, necessitates personalized management for lesions larger than 1 cm as well as for young patients and in the presence of measurable growth of the nodule. Moreover, surgery is always mandatory for small NF-PanNENs with a dilated MPD. According to the protocol, the study will be concluded 1 year after the




Fig. 1 Study flow chart

NF-PanNEN, non-functioning pancreatic neuroendocrine neoplasm.

enrolment of the last patient. Nevertheless, as these preliminary results showed only a very low rate of patients with tumour growth after a median follow-up of 2 years, longer follow-up is probably needed for definitive conclusions to be reached.

Funding

This study was funded by European Neuroendocrine Tumor Society.

Acknowledgements

The authors thank F. di Salvo (Division of Pancreatic Surgery, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy) for her contribution with acquisition and analysis of data; and the following people for their involvement in the acquisition of data: D. Horsch (Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany), J. C. Percovich (Hospital Universitario Gregorio Marañon, Madrid, Spain), S. Jamdar (Manchester University NHS Foundation Trust, Manchester, UK), M. S. Khan (University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, UK), E. N. van Dijkum (Amsterdam Medical Centre, Amsterdam, the Netherlands), E. Martin Perez (University Hospital La Princesa, Madrid, Spain), and G. Donatini (Poitiers University Hospital, Poitiers, France).

Disclosure

The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at *BJS* online.

References

1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncol* 2017;**3**:1335–1342
2. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL et al. Small, nonfunctioning, asymptomatic pancreatic

- neuroendocrine tumors (PNETs): role for nonoperative management. *Surgery* 2012;**152**:965–974
3. Sadot E, Reidy-Lagunes DL, Tang LH, Do RKG, Gonen M, D'Angelica MI et al. Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study. *Ann Surg Oncol* 2016;**23**:1361–1370
4. Barenboim A, Lahat G, Nachmany I, Nakache R, Goykhman Y, Geva R et al. Resection versus observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors. *J Gastrointest Surg* 2019;**24**:1366–1374
5. Partelli S, Cirocchi R, Crippa S, Cardinali L, Fendrich V, Bartsch DK et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. *Br J Surg* 2017;**104**:34–41
6. Heidsma CM, Engelsman AF, Van Dieren S, Stommel MWJ, de Hingh I, Vriens M et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). *Br J Surg* 2021;**108**:888–891
7. Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. *Surgery* 2011;**150**:75–82
8. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. *Neuroendocrinology* 2017;**105**:255–265
9. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. *Pancreas* 2020;**49**:1–33
10. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. *J Natl Compr Canc Netw* 2018;**16**:693–702
11. Partelli S, Mazza M, Andreasi V, Muffatti F, Crippa S, Tamburrino D et al. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: limitations to apply guidelines into real life. *Surgery* 2019;**166**:157–163
12. Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N et al. Implementation of current ENETS guidelines for surgery of small (≤ 2 cm) pancreatic neuroendocrine neoplasms in the German Surgical Community: an analysis of

- the prospective DGAV StuDoQ|Pancreas Registry. *World J Surg* 2018;**43**:175–182
13. Chivukula SV, Tierney JF, Hertl M, Poirier J, Keutgen XM. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: are we over- or undertreating patients? *Surgery* 2020;**167**:180–186
 14. Partelli S, Ramage JK, Massironi S, Zerbi A, Kim HB, Niccoli P et al. Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms (ASPEN) \leq 2 cm: study protocol for a prospective observational study. *Front Med* 2020;**7**:1–8
 15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;**240**:205–213
 16. Zhou B, Zhan C, Xiang J, Ding Y, Yan S. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection. *BMC Endocr Disord* 2019;**19**:123
 17. Partelli S, Andreasi V, Muffatti F, Schiavo Lena M, Falconi M. Circulating neuroendocrine gene transcripts (NETest): a postoperative strategy for early identification of the efficacy of radical surgery for pancreatic neuroendocrine tumors. *Ann Surg Oncol* 2020;**27**:3928–3936